Skip to content
NKCELLThe NK guide

Research & evidence

Where to Find Public Records on NK Cell Research in Japan

Japan keeps research registrations and non-research regenerative-medicine provision plans on separate public routes. Here is how to read an NK cell entry without mistaking it for approval or proof of benefit.

Japan's public record on NK (natural killer) cell work is not one list. The first fork is research versus non-research provision. The Ministry of Health, Labour and Welfare (MHLW) says in its 2025 overview of regenerative-medicine plan submissions that research-type regenerative medicine goes through jRCT, while non-research provision plans go through e-再生医療. So if you are looking for an NK cell study designed and registered as research, start with jRCT. If you are looking for a non-research plan to provide regenerative medicine, start with the e-再生医療 published plan list. The two routes answer different questions, and neither one is a product approval.

Start with the route, not the clinic name

A research entry and a provision-plan entry are not two views of the same database. MHLW's e-再生医療 application and plan entry makes the same split: research plans go through jRCT, and non-research plans go through e-再生医療. That is a routing rule, not a quality ranking.

An NK cell example makes the difference concrete. A research record can help you locate a registered study and see how the study is described. A provision-plan record can help you locate a non-research plan to provide regenerative medicine. MHLW's published list is specifically a list of notified regenerative medicine provision plans for treatment. The words on the page matter: a study registration is not a treatment offer, and a provision plan is not a trial result.

What each public route can and cannot tell you

Swipe or scroll to read the full table →

Public route What the named source says it covers What a record can help you check What it does not establish
MHLW jRCT Research-type regenerative medicine That a research study is registered or described in the route MHLW names for research That the study worked, that a product is approved, or that a patient should seek it
MHLW e-再生医療 published plan list Non-research regenerative-medicine provision plans, including treatment plans That a provision plan appears in the public list Product approval or clinical benefit
WHO ICTRP A platform for clinical trial registration information; WHO says ICTRP is not itself a registry That registered-trial information can be searched across registries A result, an approval, or a Japanese provision-plan status

MHLW’s plan list and PMDA’s review pages serve different purposes. A listing can establish that a plan was published. To check approval for a specific product, look for its PMDA record. To assess efficacy, look for clinical outcomes.

The e-再生医療 list's search index can return NK-related entries. Treat that as a lead, not a finding. A search snippet is not proof that a particular plan is current, that an institution holds a product approval, or that the plan is suitable for any patient.

Risk categories are labels, not benefit grades

MHLW's overview also refers to risk categories I, II, and III for provision plans. Read those categories as a regulatory sorting label, not a benefit grade. A category does not tell you whether an NK cell approach works, whether a product is approved, or whether a particular patient is eligible. If a record shows a category, keep it with that record and do not turn it into a clinical recommendation.

Re-read the exact record on the day you rely on it

Public listings are not frozen. A search index may show NK-related entries in the e-再生医療 treatment-plan list, but an index entry is a lead, not a same-day verification. The practical habit is to open the exact record and re-read its fields on the day you use it. If the page will not load, do not fill the gap with a snippet or an earlier memory.

When a record names a product, indication, and phase, keep those details attached to that record. Do not carry them over to a different NK entry.

Use WHO ICTRP as a finding aid, not a verdict

The World Health Organization's International Clinical Trials Registry Platform (ICTRP) can be a useful finding aid. WHO describes it as a platform for clinical trial registration information and states that ICTRP itself is not a registry. Use it to locate registered trial information, then follow the entry to the registry that holds it.

Registration is a transparency step. It is not a result, and it is not an approval. For a Japanese provision plan, the route MHLW names is e-再生医療, not ICTRP. My reading is that ICTRP is best treated as a search layer across trial registries, while the Japanese provision-plan question belongs to MHLW's separate route.

A short checklist for reading an NK cell entry

  • Identify the route first: jRCT for research-type regenerative medicine, or e-再生医療 for non-research provision plans.
  • Read the exact title and record, not a search snippet or a headline.
  • Keep product, indication, and study phase attached to the record where they appear. Do not infer missing fields.
  • Treat risk category I, II, or III as a regulatory classification, not a benefit grade.
  • Re-open the record on the day you rely on it; a registry entry is not a permanent endorsement.
  • Do not treat a trial design as a result, a registry submission as approval, or a laboratory cell assay as patient benefit.

This is general information about public records, not medical advice. For individual medical decisions, consult a qualified clinician who can review the case.

Sources and further reading

Keep reading

Follow the next question.

Research & evidence